Scientific Resources & Documentation
Access comprehensive scientific literature, technical documentation, and research data supporting the Senolyte™ Series of NAD⁺ precursors. All materials are regularly updated with the latest findings to support your formulation and regulatory needs.
Research White Papers
Comprehensive scientific documentation covering mechanisms of action, clinical efficacy, and formulation guidance
NAD⁺ Metabolism and Aging: A Comprehensive Review
In-depth analysis of NAD⁺ decline mechanisms and therapeutic intervention strategies
Bioavailability Comparison: NMN vs NMNH Clinical Study
In-depth analysis of NAD⁺ decline mechanisms and therapeutic intervention strategies
Stability Testing and Formulation Guidelines
Technical documentation for optimal storage, handling, and formulation practices
Comparative Bioavailability of NAD⁺ Precursors
Head-to-head comparison of NMN, NR, and novel derivatives including pharmacokinetic data and cellular uptake studies.
Senolytics and NAD⁺ Boosters: Synergistic Strategies for Healthy Aging
Outlines how NAD⁺ precursors can be combined with senolytic compounds for improved cellular rejuvenation.
Enhanced NAD⁺ Delivery Systems: Liposomal vs. Standard Forms
Compares absorption rates and bioefficacy between liposomal delivery and traditional oral routes.
NRK-AG: A Novel Pathway for NAD⁺ Restoration
Discusses the metabolic advantages of NRK-AG and its potential for rapid NAD⁺ replenishment.
Intracellular NAD⁺ Measurements: Methods and Validation Protocols
Details standardized testing procedures used to quantify NAD⁺ levels in preclinical and clinical studies.
Key Published Studies
Peer-reviewed research supporting the efficacy and safety of NAD⁺ precursors
Preclinical Study: NMNH Is a Highly Potent NAD⁺ Booster
Redox Biology / FASEB Journal, 2021–2022
NMNH outperformed NMN and NR in raising NAD⁺ ~9-fold in cells and animal models. It acted faster and showed superior stability with distinct metabolism
Human Clinical Pilot: Dasatinib + Quercetin Improves Mobility & Cognition
eBioMedicine, 2025
Open-label, 12‑week trial in older adults (≥65 yrs) showing intermittent DQ treatment may boost gait speed and MoCA scores in mild cognitive impairment (MCI) cases
Human Clinical Trial: Chronic NR Supplementation Elevates NAD⁺
Nature Communications, 2018
Demonstrated that daily nicotinamide riboside (500 mg twice daily for 6 weeks) safely boosted NAD⁺ metabolism and improved vascular function in healthy middle-aged adults
Review Article: NAD⁺ Precursors and Senescence Mechanisms
National Library of Medicine
Clarifies how NAD⁺ decline relates to senescent cell buildup and outlines potential roles for NR, NMN, and NMNH in mitigating aging pathways
Randomized Trial: NMN + Resveratrol Synergy (Clinical, 2024)
NMN Review Hub summary, Nakagawa et al. 2024
84 adults (50–75 yrs) for 12 weeks: combined NMN (500 mg) + resveratrol (250 mg) improved glucose tolerance 42% more vs NMN alone, increased SIRT1 activity and mitochondrial biogenesis markers
Phase II Pilot NR in Mild Cognitive Impairment
GeroScience, Feb 2024
Randomized, 8‑week trial (20 subjects, up to 1 g/day NR): NAD⁺ rose ~2.5× vs placebo. No major cognitive improvements but safe and engaged target biomarkers
Phase I Trial: High‑Dose NR in Parkinson’s Disease
Nature Communications / Nutraceuticals World, Dec 2023
1,000–3,000 mg/day NR in early Parkinson’s patients was well tolerated, raised brain NAD metabolome, and led to mild symptom improvement
